BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34160722)

  • 1. Transient left ventricular clot in COVID-19-related myocarditis is associated with hypereosinophilic syndrome: a case report.
    Ziaie N; Maleh PA; Ramandi MMA; Pourkia R; Latifi K; Mansouri D
    Int J Cardiovasc Imaging; 2021 Nov; 37(11):3279-3283. PubMed ID: 34160722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
    Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
    Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
    Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
    Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.
    Voeller J; DeNapoli T; Griffin TC
    Cancer Rep (Hoboken); 2022 Nov; 5(11):e1710. PubMed ID: 36241191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute exacerbation of idiopathic hypereosinophilic syndrome following asymptomatic coronavirus disease 2019: a case report.
    Suzuki S; Suzuki K; Ichikawa T; Takahashi K; Minami-Hori M; Tanino Y
    J Med Case Rep; 2022 Aug; 16(1):324. PubMed ID: 36042524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
    Rives S; Alcorta I; Toll T; Tuset E; Estella J; Cross NC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):663-5. PubMed ID: 16344672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Cools J; Stover EH; Gilliland DG
    Methods Mol Med; 2006; 125():177-87. PubMed ID: 16502585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
    Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
    Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
    Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
    Curto-Barredo L; Segura S; Ishii N; Hashimoto T; Mascaró JM; Espinet B; Besses C; Pujol RM
    J Dermatol; 2019 Jun; 46(6):531-534. PubMed ID: 31021002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus.
    Locke M; Suen RM; Williamson AK; Nieto MJ
    Cureus; 2023 Aug; 15(8):e43138. PubMed ID: 37692703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.
    Roufosse F; Heimann P; Lambert F; Sidon P; Bron D; Cottin V; Cordier JF
    Respiration; 2016; 91(5):374-9. PubMed ID: 27164940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome.
    Merlotto MR; Cantadori LO; Sakabe D; Miot HA
    An Bras Dermatol; 2018 Jun; 93(3):451-453. PubMed ID: 29924226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.